Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine salts

Journal of Child and Adolescent Psychopharmacology

Volumn 21, Issue 6, 2011, Pages 581-588

  Stein, Mark A ^a   Waldman, Irwin D ^b   Charney, Elizabeth ^a   Aryal, Subhash ^c   Sable, Craig ^d   Gruber, Reut ^e   Newcorn, Jeffrey H ^f  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b EMORY UNIVERSITY   (United States)

^c UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^d CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^e DOUGLAS MENTAL HEALTH UNIVERSITY INSTITUTE   (Canada)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; DEXMETHYLPHENIDATE;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DECREASED APPETITE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SUSTAINED DRUG RELEASE;

ADOLESCENT; AMPHETAMINES; APPETITE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; METHYLPHENIDATE; PSYCHIATRIC STATUS RATING SCALES; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 84555188178     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2011.0018     Document Type: Article

References (38)

1. Achenbach TM: Manual for the Child Behavior Checklist and Revised Child Behavior Prophile. Burlington, VT: University of Vermont, Department of Psychiatry; 1991.
2. American Academy of Child and Adolescent Psychiatry: Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 41:26s-48s, 2002.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV). Washington, DC: American Psychiatric Association; 1994.
4. Arnold L: Methylphenidate vs. Amphetamine: Comparative review. J Atten Disord 3:200-211, 2000.
5. Barkley R, McMurray M, Edelbrock C, Robbins ZK: Side effects of MPH in children with attention deficit hyperactivity disorder: A systematic placebo controlled evaluation. Pediatrics 86:184-192, 1990. (Pubitemid 20238848)
6. Biederman J, Gao H, Rogers AK, Spencer TJ: Comparison of parent and teacher reports of attention-deficit hyperactivity disorder symptoms from two placebo-controlled studies of atomoxetine in children. Biol Psychiatry 60:1106-1110, 2006. (Pubitemid 44647212)
7. Biederman J, Lopez FA, Boellne SW, Chandler MC: A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. Pediatrics 110:258-266, 2002. (Pubitemid 34833008)
8. Bryk AT, Raudenbush S: Hierarchical Linear Models: Applications and Data Analysis Methods. Newbury Park, Ca: Sage; 1992.
9. Buitelaar JK, Wilens TE, Zhang S, Ning Y, Feldman PD: Comparison of symptomatic versus functional changes in children and adolescents with ADHD during randomized, double-blind treatment with psychostimulants, atomoxetine, or placebo. J Child Psychol Psychiatry 50:335-342, 2009.
10. Clancy C: Comparative-effectiveness research-implications of the federal coordinating council's report. N Engl J Med 361:328-330, 2009.
11. Daughton JM, Kratochvil CJ: Review of ADHD pharmacotherapies: Advantages, disadvantages, and clinical pearls. J Am Acad Child Adolesc Psychiatry 48:240-248, 2009.
12. DuPaul G, Power TJ, Anastopoulos A, Reid R: ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretations. NY: Guilford Press; 1998.
13. Efron D, Jarman F, Barker M: Side effects of Methylphenidate and Dextroapmphetamine in children with ADHD: A double blind crossover study. Pediatrics 100:662-666, 1997. (Pubitemid 27425991)
14. Elia J, Borcherding BG, Rapoport J, Keysor C: Methylphenidate and dextroamphetamine treatment of hyperactivity: Are there true nonresponders? Psychiatry Res 36:141-155, 1991.
15. Faraone SV, Biederman J, Roe C: Comparative efficacy of Adderall and methylphenidate in attention-deficit/hyperactivity disorder: A meta-analysis. J Clin Psychopharmacol 22:468-473, 2002.
16. Faraone SV, Buitelaar J: Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry 19:353-364, 2010.
17. Garber A, Tunis SR: Does comparative-effectiveness research threaten personalized medicine? N Engl J Med 360:1925-1927, 2009.
18. Greenhill L, Kollins S, Abikoff H, McCracken J, Riddle M, Swanson J, McGough J, Wigal S, Wigal T, Vitiello B, Skrobala A, Posner K, Ghuman J, Cunningham C, Davies M, Chuang S, Cooper T: Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry 45:1284-1293, 2006a. (Pubitemid 44665445)
19. Greenhill LL, Muniz R, Ball RR, Levine A, Pestreich L, Jiang H: Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45:817-823, 2006b. (Pubitemid 43932908)
20. Greenhill LL, Swanson JM, Vitiello B, Davies M, Clevenger W, Wu M, Arnold LE, Abikoff HB, Bukstein OG, Conners CK, Elliott GR, Hechtman L, Hinshaw SP, Hoza B, Jensen PS, Kraemer HC, March JS, Newcorn JH, Severe JB, Wells K, Wigal T: Impairment and deportment responses to different methylphenidate doses in children with ADHD: The MTA titration trial. J Am Acad Child Adolesc Psychiatry 40:180-187, 2001. (Pubitemid 32111021)
21. Guy W: ECDU Assessment Manual for Psychopharmacology, Revised. Bethesda: U.S. Department of Health, Education, and Welfare; 1976.
22. Jacobson N, Truax P: Clinical significance: A statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol 59:12-19, 1991.
23. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Brent D, Williamson D, Ryan N: Schedule for affective disorder and Schizophrenia for school-age children-present and lifetime version (K-SADS-PL): Initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36:989-988, 1997.
24. Newcorn JH, Kratochvil CJ, Allen AJ, Casat CD, Ruff DD, Moore RJ, Michelson D: Atomoxetine and osmotically released methylphe-nidate for the treatment of attention deficit hyperactivity disorder: Acute comparison and differential response. Am J Psychiatry 165:721-730, 2008. (Pubitemid 351810541)
25. Newcorn JH, Stein, MA, Cooper K: Dose-response characteristics in adolescents with ADHD treated with OROS methylphenidate in a 4 week, open-label, dose titration study. J Child Adolesc Psycho-pharmacol 20:187-196, 2010.
26. Newcorn JH, Sutton V, Zhang S, Wilens T, Kratochvil CJ, Emslie G, Sutton VK, D'Souza DN, Schuh LM, Allen AJ: Characteristics of placebo responders in pediatric clinical trials of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 48:1165-1172, 2009.
27. Olfson M, Marcus S, Wan G. Stimulant dosing for children with ADHD: A medical claims analysis. J Am Acad Child Adolesc Psychiatry 48:51-59, 2009.
28. Pliszka SR, Greenhill LL, Crismon ML, Sedillo A, Carlson C, Con-ners CK, McCracken JT, Swanson JM, Hughes CW, Llana ME, Lopez M, Toprac MG: The Texas children's medication algorithm project: Report of the Texas Consensus Conference panel on medication treatment of childhood attention-deficit/ hyperactivity disorder. Part II: Tactics. Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry 39:920-927, 2000. (Pubitemid 30429925)
29. Pliszka SR, Lopez M, Crismon ML, Toprac MG, Hughes CW, Emslie GJ, Lopez M, Boemer C: A feasibility study of the children's medication algorithm project (CMAP) algorithm for the treatment of ADHD. J Am Acad Child Adolesc Psychiatry 42:279-287, 2003. (Pubitemid 39592083)
30. Solanto M, Newcorn J, Vail L, Gibert S, Ivanov I, Lara R: Stimulant drug response in predominantly inattentive and combined subtypes of attention deficit/hyperactivity disorder. J Child Adolesc Psy-chopharmcol 19:663-671, 2009.
31. Steele M, Jensen PS, Quinn DM: Remission versus response as the goal of therapy in ADHD: A new standard for the field? Clin Ther 28:1892-1908, 2006. (Pubitemid 46038524)
32. Stein MA, Sarampote CS, Waldman IW, Robb A, Conlon C, Pearl P, Black D, Seymour K, Newcorn J: A dose response study of OROS methylphenidate in children with ADHD. Pediatrics 112:3404-3413, 2003.
33. Stein MA, Szumowski E, Blondis TA, Roizen NJ: Adaptive skills dysfunction in ADD and ADHD children. J Child Psychol Psychiatry 36:663-670, 1995.
34. Swanson J: Effects of stimulant medication on hyperactive children: A review of reviews. Except Child 160:154-162, 1993.
35. Swanson JM, Hechtman L: Using long-acting stimulants: Does it change ADHD treatment outcome? Can Child Adolesc Psychiatr Rev 14:2-3, 2005.
36. Vetter VL, Elia J, Erickson C, Berger S, Blum N, Uzark K, Webb CL: Cardiovascular monitoring of children and adolescents with heart disease receiving stimulant drugs: A scientific statement from the American Heart Association Council on cardiovascular disease in the young congenital cardiac defects committee and the council on cardiovascular nursing. Circulation 117:2407-2423, 2008. (Pubitemid 351653546)
37. Weiss M, Brooks BL, Iverson GL: Reliability and Validity of the Weiss Functional Impairment Rating Scale. Presented at the American Academy of Child and Adolescent Psychiatry Annual Meeting, San Diego, CA, October 2007.
38. Wilens T, Spencer T: The stimulants revisited. Child Adolesc Psy-chiatr Clin N Am 9:573-603, 2000. (Pubitemid 30620545)